Jump to top menu Jump to main menu Jump to content
gender-neutraal-avatar
Researcher

Prof. dr. N.H. (Harry) Hendrikse

Principal Investigator

  • Department
  • Clinical Pharmacy and Radiology & Nuclear Medicine
  • Focus area
  • Translational Radiopharmacology

About Prof. dr. N.H. (Harry) Hendrikse

Introduction

Prof. dr. Harry Hendrikse is Hospital Pharmacist -Clinical Pharmacologist and full Professor at Translational Radiopharmacology. He is also Director of Cyclotron Rotterdam BV (a radiopharmaceutical holding of Erasmus MC).

He is chair of the Radiopharmaceutical Sciences Committee (RSC) of the European Association of Nuclear Medicine and member of the Medical Ethical Board of Erasmus MC.

His research focus on radiolabelled diagnostic drug development and clinical radiopharmacological evaluation performing PET imaging studies with existing or new radiolabelled drugs in several groups of patients, especially in oncology. Furthermore, we develop radiolabelled drugs for therapy of cancer patients (e.g. prostate and neuro endocrine tumors). With radiolablled drugs for diagnostic PET imaging, together with radiolabled drugs for therapy, we contributed to treatments of oncology patients by theranostics, an important topic in nuclear medicine.

He supervises several master students and PhD students, where 10 are finished. He is author of more than 185 publications. 

Field(s) of expertise

  • Clinical Radiopharmacology
  • Radiopharmaceutical drug development
  • Theranostics
  • Pharmacokinetic modelling of radiopharmaceuticals 

Education and career

He studied pharmacy at the University of Utrecht and became a pharmacist in 1994. From 1994-1999 he had a PhD position at University Medical Center Groningen (UMCG). In the last year from his PhD he started with a residency in hospital pharmacy. After finishing his PhD and residency he worked as a hospital pharmacist with special interest in radiopharmacy  in UMCG. During that period he also had a postdoc position in the PET Center of  the University hospital in Seattle, USA.  In 2005 he moved from UMCG to VU University Medical Center (VUmc) in Amsterdam as staff member of the department of hospital pharmacy and the department of Nuclear medicine. During his period in VUmc he also started with a residency in Clinical Pharmacology and finished in 2010. Since 2013 he was professor in Clinical Radiopharmacology where he supervised master students pharmacy and medicine, PhD students, postdocs, and hospital pharmacist in training.  In 2024 he moved to Erasmus MC where he has a position as Professor in Translational Radiopharmacology and director of Cyclotron Rotterdam BV. 

Publications

A complete overview of publications can be found on Pubmed.

Teaching activities

  • Lectures for Master Pharmacy students of University of Utrecht about developments in Radiopharmacy and Radiopharmacology . During this course master students pharmacy are trained in radiopharmaceutical drug development, where basic principles, but also new  insights in drug development and results in clinical studies are teached.
  • PAO (Post Academisch Onderwijs) course “Radiofarmacie en Nucleaire Geneeskunde” for hospital pharmacist and nuclear physicians in training. During this (practical  and theoretical) course basic principles for radiopharmaceuticals, including preparation and legislation  are trained (in collaboration with TU Delft).
  • Accompany theses master Pharmacy students and Medicine students.
  • Accompany internship master Pharmacy students and hospital pharmacists in training. During their training the students work within the radiopharmacy department to get knowledge about practical and theoretical radiopharmaceutical aspects.
  • As chair of the Radiopharmaceutical Committee of Europan Association of Nuclear Medicine (EANM), he develops radiopharmaceutical courses for radiopharmacists in Europe.  

Other positions

  • Chair Radiopharmacy Sciences Committee European Association of Nuclear Medicine (EANM)
  • Member Medical Ethical Board of Erasmus MC

Scholarships, grants, and awards

  • The use of [11C]erlotinib for visualization of EGFR mutated tumors and metastases in NSCLC. A feasibility study (VU 2012-5550, €553.000,00)
  • Can tumor uptake of [18F]afatinib in NSCLC patients be quantified, and does [18F]afatinib uptake identify patients who will benefit from afatinib therapy? (Boehringer Ingelheim, €291.000,00)
  • [11C]osimertinib-PET/CT to identify T790M positive tumor lesions in patients that are T790M negative in a single tumor biopsy and a circulating tumor DNA sample (Astra Zeneca, €493.000,00)
  • Guiding personalized therapy of patients with metastatic prostate cancer using a ·novel PET tracer: validation of radiolabeled PSMA (CCA/V-ICI, €194.000,00)
  • Efficacy and Safety of 177Lu-edotreotide Peptide Receptor Radionuclide Therapy (PRRT) in neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET patients) (ITG/ABX, €520.000,00)
  • Target Site Physiologically-based Pharmacokinetic Modeling in Primary and Metastatic brain Tumors to enable Tyrosine Kinase Inhibition precision Oncology & Personalized Dosing (KWF 2023-3 DEV/15486, €1.279.198,00)

My Groups